Latest News
Winners of the 2024 Proof of Principle Grant Competition
FUNDING ANNOUNCEMENT Winners of the 2024 Proof of Principle Grant Competition Christine Bear Senior Scientist, Molecular Medicine Comparison of SickKids CFTR Potentiator to Ensifentrine in Ameliorating [...]
SickKids Researcher Receives Commercialization Grant for Development of COPD Treatment
FUNDING ANNOUNCEMENT SickKids Researcher Receives Commercialization Grant for Development of COPD Treatment Dr. Christine Bear, Senior Scientist and Co-Director of the Cystic Fibrosis Centre at The Hospital for Sick Children [...]
Radiant Biotherapeutics Secures $35 Million to Advance Multabody™ Therapeutics
FUNDING ANNOUNCEMENT Radiant Biotherapeutics Secures $35 Million to Advance Multabody™ Therapeutics Industry Partnerships & Commercialization (IP&C) is excited to share that Radiant Biotherapeutics has closed [...]
SickKids Scientist Dr. Adam Shlien Secures $6 Million To Advance Cancer Diagnostic Platform
SickKids Scientist Dr. Adam Shlien Secures $6 Million To Advance Cancer Diagnostic Platform Dr. Adam Shlien, a Senior Scientist in the Genetics & Genome Biology program [...]
Exploring Immune Responses in Type One Diabetes Onset
Exploring Immune Responses in Type One Diabetes Onset Research led by Dr. Jayne Danska, Senior Scientist in the Genetics and Genome Biology program at The Hospital [...]
Radiant Biotherapeutics Secures $2M Grant for Next-Gen HIV Biologics
Radiant Biotherapeutics Secures $2M Grant for Next-Gen HIV Biologics Industry Partnerships & Commercialization (IP&C) at The Hospital for Sick Children (SickKids) is pleased to share that [...]
Accelerating Innovation: IP&C’s Eighth Annual Proof of Principle Competition Awards $300,000 to Outstanding SickKids’ Projects
Accelerating Innovation: IP&C's Eighth Annual Proof of Principle Competition Awards $300,000 to Outstanding SickKids' Projects From exploring innovative approaches for epilepsy treatment, to introducing a device [...]
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma
Breaking new ground in glioblastoma research: A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma Years [...]
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo Researchers at The Hospital for Sick Children (SickKids) have developed a novel [...]
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships Radiant Biotherapeutics, a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics [...]
